Pricing Concerns Delaying Sanofi’s Turkey Insulin Investment?
Despite the political turmoil, Sanofi appears keen to invest in the local manufacturing of an insulin product in Turkey if the government “opens the way”, but is holding off over pricing worries.
You may also be interested in...
Many local pharma companies in Turkey have been launching capital investments in new production facilities for biologics and biosimilars in the hope of attracting new foreign partners and have already met with some success, but a number of obstacles remain.
The Supreme Court in Turkey has cancelled a statute of limitations decision in a Roche legal case, with some ex-managers and bureaucrats to be retried. Meanwhile, Sanofi Turkey has become the first pharmaceutical company to export antibiotics to Japan from a production site in Turkey, the AIFD has elected a chairman, and Lilly has made new appointments.
Turkey’s efforts to control rising rates of COVID-19 are compromising the ability of hospitals to pay their debts to medtech and pharmaceutical companies. The government has devised a payments plan, but there is catch.